Aptalis Pharma US, Inc. v. Delcor Asset Corporation
1:15-cv-01210
Overview
Parties
Defendant
Renaissance Acquistion Holdings, LLC NPE (Patent Assertion Entity)
Represented By
0 Attorneys ListedDelcor Asset Corporation NPE (Individual / Inventor)
Represented By
0 Attorneys ListedPlaintiff
Aptalis Pharma Canada ULC Operating Company
Represented By
2 Attorneys ListedMorgan Lewis & Bockius LLP
1007 Orange Street, Suite 501
Aptalis Pharma US, Inc. Operating Company
Represented By
2 Attorneys ListedMorgan Lewis & Bockius LLP
1007 Orange Street, Suite 501
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 6 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7541384
Mesalamine suppository
|
Filed: 2008-10-03
Issued: 2009-06-02
|
Active (1.9 yrs remaining)
Expires: 2028-10-03
|
|
|
US8217083
Mesalamine suppository
|
Filed: 2009-06-01
Issued: 2012-07-10
|
Active (2.4 yrs remaining)
Expires: 2029-04-24
|
|
|
US8436051
Mesalamine suppository
|
Filed: 2009-12-16
Issued: 2013-05-07
|
Active (2.8 yrs remaining)
Expires: 2029-09-11
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).